Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05687266
Title Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)
Acronym AVANZAR
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | TUR | SWE | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BGR | AUT

Additional content available in CKB BOOST